表纸
市场调查报告书

焦点市场分析:麸质过敏症

Market Spotlight: Celiac Disease

出版商 Datamonitor Healthcare 商品编码 633145
出版日期 内容资讯 英文 30 Pages
商品交期: 最快1-2个工作天内
价格
焦点市场分析:麸质过敏症 Market Spotlight: Celiac Disease
出版日期: 2019年11月18日内容资讯: 英文 30 Pages
简介

全球麸质过敏症的患病人数预测将从2016年约8850万人,增加到2025年的9740万人。

本报告提供全球麸质过敏症的治疗药的市场调查,汇整疾病的背景·概要,患病人数的十年预测,主要的治疗方法,主要的开发平台药物概要,授权·资产收购等企业间的主要交易趋势,专利资讯,临床试验状况等资料。

概要

主要的要点

疾病的背景

  • 亚型

治疗

流行病学

开发平台药物

今后主要的活动

授权·资产收购契约

  • 由于武田药品工业的资金供给·有可能准备收购

本源专利

临床试验环境

文献

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: DMKC0181038

This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 89.9 million prevalent cases of celiac disease worldwide, and forecasts that number to increase to 98.8 million prevalent cases by

2026. Prevalence of celiac disease is highest in Europe and Northern America, and lowest in Africa and Oceania. The majority of industry-sponsored drugs in active clinical development for celiac disease are in Phase II, with only one drug in Phase III.

Therapies in development for celiac disease focus on targets such as zonulin and zonulin receptor, interleukin-15, interleukin-15 receptor, and gluten. Pipeline drugs for celiac disease are administered via the oral and intravenous routes.

The release of topline Phase III trial results for INN-202 is the only high-impact upcoming event in the celiac disease space. The overall likelihood of approval of a Phase I autoimmune/immunology asset is 13.6%, and the average probability a drug advances from Phase III is 68.3%. Drugs, on average, take 9.0 years from Phase I to approval in the overall autoimmune/immunology space.

There have been seven licensing and asset acquisition deals involving celiac disease drugs during 2014-19. The largest deal during the period was the $800m collaboration and license agreement signed in May 2019 between Parvus and Genentech to develop, manufacture, and commercialize novel Navacim therapeutics for the treatment of inflammatory bowel disease, autoimmune liver diseases, and celiac disease.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for celiac disease have been in the mid and late phases of development, with 91% of trials in Phase II-III, and only 9% in Phase I.

The US has the highest number of celiac disease clinical trials globally. Clinical trial activity in the celiac disease space is dominated by completed trials. Innovate Biopharmaceuticals has the highest number of completed clinical trials for celiac disease, with six trials.

Innovate Biopharmaceuticals leads industry sponsors with the highest overall number of clinical trials for celiac disease.

TABLE OF CONTENTS

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

7 Subtypes

9 TREATMENT

10 EPIDEMIOLOGY

14 PIPELINE DRUGS

18 RECENT EVENTS AND ANALYST OPINION

18 TAK-101 for Celiac Disease (October 21, 2019)

20 KEY UPCOMING EVENTS

21 PROBABILITY OF SUCCESS

22 LICENSING AND ASSET ACQUISITION DEALS

22 Takeda Adds Celiac Disease Candidate To GI Efforts

22 Anokion Acquires Its Own Spinout, Kanyos

23 GSK Buys One Of Eight Firms Formed In VC Partnership With Avalon

23 Parvus, Genentech Collaborate On IBD, Celiac And Liver Disease

24 CLINICAL TRIAL LANDSCAPE

25 Sponsors by status

26 Sponsors by phase

26 Phase II Study Shows Antigen-Specific Immune Tolerance Is Possible In Autoimmune Diseases

28 BIBLIOGRAPHY

29 APPENDIX

LIST OF FIGURES

  • 12 Figure 1: Trends in prevalent cases of celiac disease, 2017-26
  • 14 Figure 2: Overview of pipeline drugs for celiac disease in the US
  • 14 Figure 3: Pipeline drugs for celiac disease, by company
  • 15 Figure 4: Pipeline drugs for celiac disease, by drug type
  • 15 Figure 5: Pipeline drugs for celiac disease, by classification
  • 19 Figure 6: TAK-101 for Celiac Disease (October 21, 2019): Phase IIa - Safety & Efficacy
  • 20 Figure 7: Key upcoming events in celiac disease
  • 21 Figure 8: Probability of success in the celiac disease pipeline
  • 22 Figure 9: Licensing and asset acquisition deals in celiac disease, 2014-19
  • 24 Figure 10: Clinical trials in celiac disease
  • 24 Figure 11: Top 10 drugs for clinical trials in celiac disease
  • 25 Figure 12: Top 10 companies for clinical trials in celiac disease
  • 25 Figure 13: Trial locations in celiac disease
  • 26 Figure 14: Celiac disease trials status
  • 26 Figure 15: Celiac disease trials sponsors, by phase

LIST OF TABLES

  • 11 Table 1: Prevalent cases of celiac disease, 2017-26
  • 13 Table 2: Prevalence proportions of celiac disease, by age group, 2017
  • 16 Table 3: Pipeline drugs for celiac disease in the US
  • 18 Table 4: TAK-101 for Celiac Disease (October 21, 2019)